Rznomics announced on october 11th,2022 that it had received approval for phase 1 and 2 clinical trial (IND) of 'RZ-001' from the US Food and Drug Administration (FDA).

The clinical trial plan was approved by the Ministry of Food and Drug Safety in June,2022 and is an extension of the ongoing domestic clinical trial.

Rznomics has the technology to express the desired gene while removing the target ribonucleic acid (RNA) based on RNA trans-splicing ribozyme.

RZ-001 targets telomerase (hTERT) RNA specifically expressed in cancer cells by delivering a ribonucleic acid substitution enzyme to an adenovirus vector.

At the same time, it is a mechanism for expressing genes that induce anticancer activity.

Rznomics is pushing to expand indications to other carcinomas, and is planning a clinical trial for malignant glioblastoma within this year.

In addition to the anticancer drug pipeline, Rznomics is developing therapeutics in various fields using platform technology, such as Alzheimer's treatment, hereditary retinopathy, and Rett's syndrome.

Seongwook Lee, CEO of Rznomics, said, "The pipelines under development are scheduled to begin clinical trials in korea and abroad sequentially, and we will do our best to provide new treatment opportunities to patients."